IBR2 is a recognized Rad51 inhibitor to impair Rad51 multimerization and promote proteasome-mediated degradation of Rad51 protein to therefore reduce HRR function, which ultimately enhances apoptosis and impairs tumor growth of chronic myeloid leukemia (60). The gene discussed is RAD51; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.